Pharmaceutical Following the latest draft guidance from the UK's National Institute for Health and Clinical Excellence (NICE) on drugs for the treatment of chronic myeloid leukemia, which took a somewhat negative, cost-related, stance on the use of Novartis' Tasigna (nilotinib) and Bristol-Myers Squibb's Sprycel (dasatinib) for use under the National Health Service in patients who are intolerant to Glivec (imatinib), also from Novartis (The Pharma Letter February 9), the patient group, the Chronic Myeloid Leukemia Support group, has put up a strong argument for the two drugs. 24 February 2010